Literature DB >> 11593114

Relation between clinical and therapeutic variables and quality of life in hypertension.

A Roca-Cusachs1, A Dalfó, X Badia, I Arístegui, M Roset.   

Abstract

OBJECTIVE: Study the relation between quality of life (QoL) and various clinical, therapeutic and sociodemographic variables in treated hypertensive patients.
MATERIAL AND METHODS: A prospective study was carried out in 92 primary care centres in Spain. A total of 269 hypertensive patients were selected and 106 healthy normotensive individuals were included as controls. At the time of inclusion a wide range of clinical variables was documented. QoL was assessed at baseline and 1 month after the intensification of antihypertensive therapy, using a self-administered, specific hypertension, 56-item questionnaire in addition to the generic EuroQoL-5D.
RESULTS: QoL was poorer among the hypertensive subjects than among the normotensive individuals, even adjusting for the differences observed between the groups (age, sex, education and working status). The same was found with the EuroQol-5D. In the hypertensive subjects, after applying a multiple regression equation, only four variables significantly retained their negative impact on QoL: sex (female), greater organ damage and higher heart rate and weight. After the intensification of antihypertensive therapy with irbesartan, QoL improved significantly. Neither the presence of side-effects during the month of follow-up, nor the degree of BP reduction showed a significant impact on QoL, although the latter came close to statistical significance.
CONCLUSIONS: Hypertensive patients have significantly poorer QoL than normotensive subjects, even with adjustment for differences. In hypertensives, QoL is affected by some clinical variables that might help us to identify those with worse QoL. Intensification of antihypertensive therapy produced a positive impact on QoL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11593114     DOI: 10.1097/00004872-200110000-00028

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  4 in total

Review 1.  Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers).

Authors:  Antonio Coca
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

2.  The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States.

Authors:  Patrick W Sullivan; Vahram H Ghushchyan; Rami Ben-Joseph
Journal:  Qual Life Res       Date:  2008-09-08       Impact factor: 4.147

3.  Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension.

Authors:  Pedro Marques da Silva; Uwe Haag; Julian F Guest; John E Brazier; Marco Soro
Journal:  Health Qual Life Outcomes       Date:  2015-02-21       Impact factor: 3.186

4.  Cross-cultural adaptation of the Spanish MINICHAL instrument into English for use in the United Kingdom.

Authors:  Andrew N Jordan; Christine Anning; Lindsay Wilkes; Claire Ball; Nicola Pamphilon; Christopher E Clark; Nicholas G Bellenger; Angela C Shore; Andrew S P Sharp; Jose M Valderas
Journal:  Health Qual Life Outcomes       Date:  2022-03-04       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.